Creatine supplementation with methylglyoxal: a potent therapy for cancer in experimental models
The DOI matches its Crossref record; 48 of the 51 references it cites were found in a registry or an index.
Abstract
The anti-cancer effect of methylglyoxal (MG) is now well established in the literature. The main aim of this study was to investigate the effect of creatine as a supplement in combination with MG both in vitro and in vivo. In case of the in vitro studies, two different cell lines, namely MCF-7 (human breast cancer cell line) and C2C12 (mouse myoblast cell line) were chosen. MG in combination with creatine showed enhanced apoptosis as well as higher cytotoxicity in the breast cancer MCF-7 cell line, compared to MG alone. Pre-treatment of well-differentiated C2C12 myotubes with cancerogenic 3-methylcholanthrene (3MC) induced a dedifferentiation of these myotubes towards cancerous cells (that mimic the effect of 3MC observed in solid fibro-sarcoma animal models) and subsequent exposure of these induced cancer cells with MG proved to be cytotoxic. Thus, creatine plus ascorbic acid enhanced the anti-cancer effects of MG. In contrast, when normal C2C12 muscle cells or myotubes (mouse normal myoblast cell line) were treated with MG or MG plus creatine and ascorbic acid, no detrimental effects were seen. This indicated that cytotoxic effects of MG are specifically limited towards cancer cells and are further enhanced when MG is used in combination with creatine and ascorbic acid. For the in vivo studies, tumors were induced by injecting Sarcoma-180 cells (2 × 10(6) cells/mouse) in the left hind leg. After 7 days of tumor inoculation, treatments were started with MG (20 mg/kg body wt/day, via the intravenous route), with or without creatine (150 mg/kg body wt/day, fed orally) and ascorbic acid (50 mg/kg body wt/day, fed orally) and continued for 10 consecutive days. Significant regression of tumor size was observed when Sarcoma-180 tumor-bearing mice were treated with MG and even more so with the aforesaid combination. The creatine-supplemented group demonstrated better overall survival in comparison with tumor-bearing mice without creatine. In conclusion, it may be stated that the anti-cancer effect of MG is enhanced by concomitant creatine supplementation, both in chemically transformed (by 3MC) muscle cells in vitro as well as in sarcoma animal model in vivo. These data strongly suggest that creatine supplementation may gain importance as a safe and effective supplement in therapeutic intervention with the anti-cancer agent MG.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“reduce the progress of some forms of cancer [8,17,18,135,144,145,146,147];”
From Creatine in health and disease (2021) · cites this paper as [147]
In the citing paper
“Prior studies have shown that creatine content and energy availability are low in several types of malignant cells and T cells that mediate the immune responses against cancer [17,18,144,145,147].”
From Creatine in health and disease (2021) · cites this paper as [147]
Citations
Cites
Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104
Creatine and Creatinine Metabolism
Wyss, M., & Kaddurah-Daouk, R. (2000) · Physiological Reviews · doi:10.1152/physrev.2000.80.3.1107 · Cited by 2,950
Wallimann, T., Wyss, M., Brdiczka, D., Nicolay, K., & Eppenberger, H. M. (1992) · Biochemical Journal · doi:10.1042/bj2810021 · Cited by 2,011
Chen, Q., Espey, M. G., Krishna, M. C., Mitchell, J. B., Corpe, C. P., Buettner, G. R., Shacter, E., & Levine, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506390102 · Cited by 1,075 · cited 1×
“There are reports in literature that ascorbic acid at a low concentration has no effect on cancer cells (Ray and Ray 1998), but it shows significant cytotoxicity towards cancer cells at very high concentration (Chen et al. 2005; Du et al. 2012).”
BackgroundAscorbic acid: Chemistry, biology and the treatment of cancer
Du, J., Cullen, J. J., & Buettner, G. R. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.06.003 · Cited by 1,070 · cited 3×
“Neither creatine (150 mg/kg body wt/day) nor ascorbic acid (50 mg/kg body wt/day) alone has any significant effect on cancer cells (Du et al. 2012; Ray and Ray 1998).”
BackgroundCardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention
Albini, A., Pennesi, G., Donatelli, F., Cammarota, R., De Flora, S., & Noonan, D. M. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp440 · Cited by 839 · cited 1×
“1 3 There are several reports in literature that have described the cardiotoxicity of specific classes of cancer therapeutic agents and cardiovascular toxic effects as important complications during cancer chemotherapy (Albini et al. 2010).”
BackgroundThe creatine kinase system and pleiotropic effects of creatine
Wallimann, T., Tokarska-Schlattner, M., & Schlattner, U. (2011) · Amino Acids · doi:10.1007/s00726-011-0877-3 · Cited by 797
Direct antioxidant properties of creatine
Lawler, J. M., Barnes, W. S., Wu, G., Song, W., & Demaree, S. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.6164 · Cited by 448 · cited 1×
“Furthermore, recent studies have demonstrated a protective effect of creatine due to its direct oxygen-radical scavenging capacity (Lawler et al. 2002) and indirect antioxidant effects (Sestili et al.”
BackgroundExtracellular Metabolic Energetics Can Promote Cancer Progression
Loo, J. M., Scherl, A., Nguyen, A., Man, F. Y., Weinberg, E., Zeng, Z., Saltz, L., Paty, P. B., & Tavazoie, S. F. (2015) · Cell · doi:10.1016/j.cell.2014.12.018 · Cited by 393
New insights into doxorubicin-induced cardiotoxicity: The critical role of cellular energetics
Tokarska-Schlattner, M., Zaugg, M., Zuppinger, C., Wallimann, T., & Schlattner, U. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.06.009 · Cited by 350 · cited 1×
“Anthracyclines like doxorubicin interfere strongly with cardiac energetics (Tokarska-Schlattner et al. 2006), and can lead to congestive heart failure (CHF).”
BackgroundSestili, P., Martinelli, C., Colombo, E., Barbieri, E., Potenza, L., Sartini, S., & Fimognari, C. (2011) · Amino Acids · doi:10.1007/s00726-011-0875-5 · Cited by 200 · cited 1×
“2002) and indirect antioxidant effects (Sestili et al. 2011).”
Kinoshita, Y., & Yokota, A. (1997) · NMR in Biomedicine · doi:10.1002/(sici)1099-1492(199701)10:1<2::aid-nbm442>3.0.co;2-n · Cited by 192
Eriksson, B. K., Skogseid, B. M., Lundqvist, G., Wide, L., Wilander, E., & Öberg, K. (1990) · Cancer · doi:10.1002/1097-0142(19900501)65:9<2014::aid-cncr2820650922>3.0.co;2-s · Cited by 167
Levels of creatine kinase and its BB isoenzyme in lung cancer specimens and cultures.
Gazdar, A. F., ZWEIG, M. H., Carney, D. N., Steirteghen, A. C. V., Baylin, S. B., & Minna, J. D. (1981) · PubMed · Cited by 148
Van Pilsum, J. F., Stephens, G. C., & Taylor, D. (1972) · Biochemical Journal · doi:10.1042/bj1260325 · Cited by 108
Biswas, S., Manju, R. A. Y., Misra, S., Dutta, D., & Ray, S. (1997) · Biochemical Journal · doi:10.1042/bj3230343 · Cited by 104
Cancerostatic Action of Methylglyoxal
Egyuud, L. G., & Szent-Gyorgyi, A. (1968) · Science · doi:10.1126/science.160.3832.1140 · Cited by 101
Lehnhardt, F., Bock, C., Röhn, G., Ernestus, R., & Hoehn, M. (2005) · NMR in Biomedicine · doi:10.1002/nbm.968 · Cited by 97
Balasubramani, M., Day, B. W., Schoen, R. E., & Getzenberg, R. H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3771 · Cited by 87 · cited 1×
“1990) and a high activity of the BCK isoform has also been reported in other malignancies (Gazdar et al. 1981; Zarghami et al. 1996; Meffert et al. 2005; Balasubramani et al. 2006).”
BackgroundElevated serum creatine kinase BB levels in patients with small cell lung cancer.
Carney, D. N., ZWEIG, M. H., Ihde, D. C., Cohen, M. H., Makuch, R., & Gazdar, A. F. (1984) · PubMed · Cited by 83
Inhibition of rate of tumor growth by creatine and cyclocreatine
Miller, E. E., Evans, A. E., & Cohn, M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3304 · Cited by 82
Wallimann, T., Tokarska‐Schlattner, M., Neumann, D., Epand, R. M., Epand, R. F., Andres, R. H., Widmer, H. R., Hornemann, T., Saks, V., Agarkova, I., et al. (2007) · Molecular System Bioenergetics · doi:10.1002/9783527621095.ch7 · Cited by 80
Proton magnetic resonance spectroscopy of choroid plexus tumors in children
Horská, A., Uluğ, A. M., Melhem, E. R., Filippi, C. G., Burger, P. C., Edgar, M. A., Souweidane, M. M., Carson, B. S., & Barker, P. B. (2001) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.1154 · Cited by 76
Enhancement of acetaldehyde-protein adduct formation by l-ascorbate
Tuma, D. J., Donohue, T. M., Medina, V. A., & Sorrell, M. F. (1984) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(84)90283-2 · Cited by 70 · cited 1×
“It facilitates the formation of protein adducts (Tuma et al. 1984), acts synergistically with MG (Ray et al.”
BackgroundPayne, R. M., Haas, R. C., & Strauss, A. W. (1991) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/0167-4781(91)90176-m · Cited by 70
Szent‐Györgyi, A. (1979) · Novartis Foundation Symposia · doi:10.1002/9780470720493.ch2 · Cited by 70
In vivo assessment of toxicity and pharmacokinetics of methylglyoxal
Ghosh, M., Talukdar, D., Ghosh, S., Bhattacharyya, N., Ray, M., & Ray, S. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2005.07.003 · Cited by 70
Patra, S., Ghosh, A., Roy, S. S., Bera, S., Das, M., Talukdar, D., Ray, S., Wallimann, T., & Ray, M. (2012) · Amino Acids · doi:10.1007/s00726-011-0974-3 · Cited by 64
Halder, J., Ray, M., & Ray, S. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910540315 · Cited by 63 · cited 1×
“MG itself has been shown to affect cancer cell growth by inhibiting glycolysis (Halder et al. 1993).”
BackgroundMolecular System Bioenergetics: Energy for Life
(2007) · Wiley eBooks · doi:10.1002/9783527621095 · Cited by 61
Creatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients
Zarghami, N., Giai, M., Yu, H., Roagna, R., Ponzone, R., Katsaros, D., Sismondi, P., & Diamandis, E. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.66 · Cited by 55 · cited 1×
“1990) and a high activity of the BCK isoform has also been reported in other malignancies (Gazdar et al. 1981; Zarghami et al. 1996; Meffert et al. 2005; Balasubramani et al. 2006).”
BackgroundKristensen, C. A., Askenasy, N., Jain, R. K., & Koretsky, A. P. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690045 · Cited by 54
Patra, S., Bera, S., SinhaRoy, S., Ghoshal, S., Ray, S., Basu, A., Schlattner, U., Wallimann, T., & Ray, M. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06475.x · Cited by 52
Elevated creatine kinase activity in primary hepatocellular carcinoma
Meffert, G., Gellerich, F. N., Margreiter, R., & Wyss, M. (2005) · BMC Gastroenterology · doi:10.1186/1471-230x-5-9 · Cited by 46 · cited 1×
“1990) and a high activity of the BCK isoform has also been reported in other malignancies (Gazdar et al. 1981; Zarghami et al. 1996; Meffert et al. 2005; Balasubramani et al. 2006).”
BackgroundRay, M., Halder, J., Dutta, S. K., & Ray, S. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910470421 · Cited by 43 · cited 1×
“1984), acts synergistically with MG (Ray et al. 1991) and augments the anticancer activity of MG (Ghosh et al.”
BackgroundFerreira‐da‐Silva, F., Pereira, P. J. B., Gales, L., Roessle, M. W., Svergun, D. I., Moradas‐Ferreira, P., & Damas, A. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605267200 · Cited by 42 · cited 1×
“It is well established from various laboratories that GAPDH from normal tissue sources has a MW of 145 kDa, with four equal subunits of 36 kDa each (Ferreira-da-Silva et al. 2006).”
BackgroundInactivation of glyceraldehyde-3-phosphate dehydrogenase of human malignant cells by methylglyoxal
Ray, M., Basu, N., & Ray, S. (1997) · Molecular and Cellular Biochemistry · doi:10.1023/a:1006831511527 · Cited by 29
Roy, S. S., Biswas, S., Ray, M., & Subhankar, R. A. Y. (2003) · Biochemical Journal · doi:10.1042/bj20021576 · Cited by 28
Das, M., Bag, A. K., Saha, S., Ghosh, A., Dey, S. K., Das, P., Mandal, C., Ray, S., Chakrabarti, S., Ray, M., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2172-x · Cited by 27
Kornacker, M., Schlattner, U., Wallimann, T., Verneris, M. R., Negrin, R. S., Kornacker, B., Staratschek‐Jox, A., Diehl, V., & Wolf, J. (2001) · International Journal of Cancer · doi:10.1002/ijc.1502 · Cited by 25 · cited 2×
“It was also reported that cyclo-creatine inhibits proliferation of Hodgkin disease-derived cell lines in an apoptosis-independent pathway and it was postulated that this creatine analogue, would therefore be advantageous in cancer therapy (Kornacker et al. 2001).”
BackgroundCreatine Supplementation Reduces Doxorubicin-Induced Cardiomyocellular Injury
Santacruz, L., Darrabie, M. D., Mantilla, J. G., Mishra, R., Feger, B. J., & Jacobs, D. O. (2014) · Cardiovascular Toxicology · doi:10.1007/s12012-014-9283-x · Cited by 24
Ghosh, A., Bera, S., Ghosal, S., Ray, S., Basu, A., & Ray, M. (2011) · Biochemistry (Moscow) · doi:10.1134/s0006297911090100 · Cited by 23
The Metabolic Milieu of Metastases
Sullivan, W. J., & Christofk, H. R. (2015) · Cell · doi:10.1016/j.cell.2015.01.023 · Cited by 19
Ray, S., Biswas, S., & Ray, M. (1997) · Molecular and Cellular Biochemistry · doi:10.1023/a:1006879816510 · Cited by 18
Glyceraldehyde‐3‐phosphate dehydrogenase from Ehrlich ascites carcinoma cells
Bagui, S., Ray, M., & Ray, S. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00384.x · Cited by 18
Molecular characterization of tumor associated glyceraldehyde-3-phosphate dehydrogenase
Patra, S., Ghosh, S., Bera, S., Roy, A., Ray, S., & Ray, M. (2009) · Biochemistry (Moscow) · doi:10.1134/s0006297909070037 · Cited by 14
Increased expression of nonmuscle myosin IIs is associated with 3MC‐induced mouse tumor
Saha, S., Dey, S. K., Das, P., & Jana, S. S. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08306.x · Cited by 11 · cited 1×
“For induction of tumorigenesis phase, differentiated myotubes were transformed with 50 nM 3MC (3-methylcholanthrene) in DMSO (dimethylsulfoxide) or with DMSO only (vehicle alone), in a fresh differentiation medium containing 2 % horse serum for another 3 days (Saha et al. 2011).”
MethodReview of Surgery: Basic Science and Clinical Topics for ABSITE
Mostafa, G., Cathey, L., & Greene, F. L. (2006) · DIAL (Catholic University of Leuven) · doi:10.1007/978-0-387-44952-4 · Cited by 6
Research works printed but not linked: 1
- Ray M, Ray S (1998) Methylglyoxal: from putative intermediate of glucose breakdown to its role in understanding that excessive ATP formation in cells may lead to malignancy. Curr Sci 75:103–113
Cited by
Wu, G. (2020) · Amino Acids · doi:10.1007/s00726-020-02823-6 · Cited by 475
Delivery systems for antimicrobial peptides
Nordström, R., & Malmsten, M. (2017) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2017.01.005 · Cited by 246
Creatine in health and disease
Kreider, R. B., & Stout, J. R. (2021) · Nutrients · doi:10.3390/nu13020447 · Cited by 227
“Prior studies have shown that creatine content and energy availability are low in several types of malignant cells and T cells that mediate the immune responses against cancer [17,18,144,145,147].”
BackgroundFood-derived 1,2-dicarbonyl compounds and their role in diseases
Hellwig, M., Gensberger‐Reigl, S., Henle, T., & Pischetsrieder, M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.014 · Cited by 156
The two sides of creatine in cancer
Zhang, L., & Bu, P. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.11.004 · Cited by 84
Metadata
- Authors
- Pal, A., Roy, A., & Ray, M.
- Affiliations
- Bose Institute (IN)
- Corresponding author
- Ray, Manju
- Venue
- Amino Acids
- Published
- 2016-04-30
- Volume
- 48
- Issue
- 8
- Pages
- 2003-2013
- ISSN
- 0939-4451 (ISSN-L)
- 1438-2199
- OpenAlex
- W2342620321
- Cited by
- 15
- References
- 51
- Citations by year
- 2024: 3 · 2021: 4 · 2020: 3 · 2018: 1 · 2017: 3 · 2016: 1
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Amino Acids (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Council for Scientific and Industrial Research ,India
- University Grant Commision,India
- Department of Science and Technology,India
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer and biochemical research
- Keywords
- methylglyoxal, creatine supplementation, vitamin C, cancer therapy, apoptosis, cytotoxicity, 3-methylcholanthrene, sarcoma 180, tumor regression, overall survival, breast cancer, muscle cells, combination therapy, oxidative stress, lipid peroxidation, protein carbonylation
- MeSH terms
- Animals, Creatine, Humans, Methylcholanthrene, Neoplasms, Experimental, Pyruvaldehyde, Mice, MCF-7 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.